- Home
- ATOS vs LGCY Comparison
ATOS vs LGCY Comparison
Compare ATOS & LGCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- LGCY
- Stock Information
- Founded
- ATOS 2009
- LGCY 2009
- Country
- ATOS United States
- LGCY United States
- Employees
- ATOS N/A
- LGCY N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- LGCY
- Sector
- ATOS Health Care
- LGCY
- Exchange
- ATOS Nasdaq
- LGCY NYSE
- Market Cap
- ATOS 96.8M
- LGCY 89.1M
- IPO Year
- ATOS 2012
- LGCY 2024
- Fundamental
- Price
- ATOS $0.89
- LGCY $7.51
- Analyst Decision
- ATOS Strong Buy
- LGCY Strong Buy
- Analyst Count
- ATOS 3
- LGCY 2
- Target Price
- ATOS $7.13
- LGCY $10.65
- AVG Volume (30 Days)
- ATOS 611.2K
- LGCY 41.2K
- Earning Date
- ATOS 05-13-2025
- LGCY 05-15-2025
- Dividend Yield
- ATOS N/A
- LGCY N/A
- EPS Growth
- ATOS N/A
- LGCY 44.62
- EPS
- ATOS N/A
- LGCY 0.58
- Revenue
- ATOS N/A
- LGCY $52,722,310.00
- Revenue This Year
- ATOS N/A
- LGCY $33.77
- Revenue Next Year
- ATOS N/A
- LGCY $24.88
- P/E Ratio
- ATOS N/A
- LGCY $12.95
- Revenue Growth
- ATOS N/A
- LGCY 32.68
- 52 Week Low
- ATOS $0.55
- LGCY $3.60
- 52 Week High
- ATOS $1.74
- LGCY $10.37
- Technical
- Relative Strength Index (RSI)
- ATOS 64.44
- LGCY N/A
- Support Level
- ATOS $0.78
- LGCY N/A
- Resistance Level
- ATOS $0.92
- LGCY N/A
- Average True Range (ATR)
- ATOS 0.06
- LGCY 0.00
- MACD
- ATOS 0.01
- LGCY 0.00
- Stochastic Oscillator
- ATOS 81.82
- LGCY 0.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.